entertainment -WSS

entertainment

author：Wikipedia 2025-09-30 00:46:06 - browse：644

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — Illustration: Alex Hogan/STAT; Photo: Eisai via AP

Seven months after US drug regulators fully approved Biogen’s treatment for Alzheimer’s disease, only about 2,000 patients are taking the medicine nationwide, the company said Tuesday.

Biogen’s chief executive, Christopher A. Viehbacher, said as the firm released fourth-quarter earnings that he had expected the slow uptake and sees considerable demand for the medication. He told reporters that 3,800 patients with early-stage Alzheimer’s have signed up on multiple registries to receive the drug, called Leqembi, as of last month.

Before patients can get the drug, which costs $26,500-a-year, they must undergo a brain scan or a spinal tap to confirm that they have build-up of deposits of a sticky toxic protein called beta-amyloid that is a hallmark of the disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Cano Health’s bankruptcy is a warning for Medicare Advantage

hotspot

focus

hotspot

WSS

First over

For AI in health care standards, federal regulators join with industry group

A new approach to psychiatric drug development

Ancient Greek ideas underpin modern concepts of pregnancy

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Global cancer cases to surge 77% by 2050, WHO report says

focus

entertainment

hotspot

Alkermes shareholders re

The CDC's new social media misinformation war

How one medical school became remarkably diverse

The Biogen Aduhelm mess could happen again

Moonlake's readout produced a cash windfall. Risks remain

Updated Covid vaccine has 54% effectiveness, new study suggests

DIEP, the 'gold standard' of breast reconstruction, is under threat

First over

At least 13 dead in Texas as scorching temps continue

Fetal cell organoids grown from amniotic fluid, study finds

leisure time

Fetal cell organoids grown from amniotic fluid, study finds

Readout Newsletter: BridgeBio, Akero, and human embryo models

AI gets buy

Stem cell biologist probes earliest stages of human development

Readout LOUD: Venture capital, Gilead, and more M&A

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

hotspot

focus

hotspot

Wikipedia